High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Atkins, Michael B ^a,e   Kunkel, Lori ^b,c   Sznol, Mario ^d   Rosenberg, Steven A ^d  

^a HARVARD UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c GENENTECH INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Interleukin 2; Melanoma

Indexed keywords

RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; FOLLOW UP; MORTALITY; SURVIVAL RATE;

FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; MELANOMA; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 0033848628     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
2. Margolin KA, Rayner AA, Hawkins MJ et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-498.
3. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:486-498.
4. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-696.
5. Fisher RI, Rosenberg SA, Sznol M et al. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997;3[suppl 1]:S70-S72.
6. Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 1984;53:1299-1305.
7. Ahmann DL, Creagan ET, Hahn RG et al. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989;63:224-227.
8. Margolin K. The clinical toxicities of high-dose interleukin-2. In: Atkins M, Mier JW, eds. Therapeutic Applications of Interleukin-2. New York: Marcel Dekker, 1993:331-362.
9. Schwartzentruber DJ. Biologic therapy with interleukin-2. In: DeVita V, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer (2nd ed). Philadelphia: JB Lippincott Co, 1995:235-249.
10. Klempner MS, Noring R, Mier JW et al. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990;322:959-965.
11. Klempner MS, Snydman DR. Infectious complications associated with interleukin-2. In: Atkins MB, Mier JW, eds. Therapeutic Applications of Interleukin-2. New York: Marcel Dekker, 1993:409-424.
12. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998;83:797-805.
13. Mier JW, Vachino G, Klempner MS et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990;76:1933-1940.
14. Trehu EG, Mier JW, Dubois JS et al. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res 1996;2:1341-1351.
15. Du Bois JS, Trehu EG, Mier JW et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997;15:1052-1062.
16. McDermott DF, Trehu EG, Mier JW et al. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin Cancer Res 1998;4:1203-1213.
17. Margolin K, Atkins M, Sparano J et al. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997;3:565-572.
18. Kemeny MM, Botchkina GI, Ochani M et al. The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Proc Natl Acad Sci USA 1998;95:4561-4566.
19. Kilbourn RG, Fonseca GA, Griffith OW et al. NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 1995;23:1018-1024.
20. Sleijfer DT, Janssen RA, Buter J et al. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 1992;10:1119-1123.
21. Atzpodien J, Lopez Hanninen E, Kirchner H et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995;13:497-501.
22. Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12:1572-1576.
23. Chapman PB, Parkinson DR, Kirkwood JM. Biologic therapy. In: Balch CM, Houghton AN, Sober AJ et al, eds. Cutaneous Melanoma (3rd ed). St. Louis: Quality Medical Publishing, Inc, 1997:419-436.
24. Atkins MB. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Kirkwood JM, ed. Molecular Diagnosis, Prevention & Therapy of Melanoma. New York: Marcel Dekker, 1998:219-251.
25. Buzaid AC, Bedikian A, Houghton AN. Systemic chemotherapy and biochemotherapy. In: Balch CM, Houghton AN, Sober AJ et al, eds. Cutaneous Melanoma (3rd ed). St. Louis: Quality Medical Publishing, Inc, 1997:405-418.
26. Legha SS, Ring S, Eton O et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-1759.
27. McDermott DF, Mier JW, Lawrence DP et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), interleukin-2 (IL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1998;17:507a.
28. O'Day SJ, Boasberg P, Guo M et al. Phase II trial of concurrent biochemotherapy (c-BC) with decrescendo interleukin-2 (d-IL-2), tamoxifen (T), and G-CSF support in patients with metastatic melanoma (MM) [abstract]. Proc Am Soc Clin Oncol 1997;16:490.
29. Thompson JA, Gold PJ, Markowitz DR et al. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 1997;3[suppl 1]:S29-S34.
30. Flaherty LE, Atkins M, Sosman J et al. Randomized phase II trial of chemotherapy and outpatient biotherapy with interleukin-2 (IL-2) and interferon alpha (IFN) in metastatic malignant melanoma [abstract]. Proc Am Soc Clin Oncol 1999;18:536a.
31. Keilholz U, Goey SH, Punt CJ et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579-2588.
32. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968-975.
33. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998;4:321-327.